Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease

Inflammatory Bowel Diseases

Volumn 12, Issue 8, 2006, Pages 745-749

  Fakhoury, May ^a   Lecordier, Julien ^b   Medard, Yves ^a   Peuchmaur, Michel ^a   Jacqz Agrain, Evelyne ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b Jean Monnet Hospital   (France)

Author keywords

Crohn's disease; CYP3A; mRNA expression; P glycoprotein

Indexed keywords

CORTICOSTEROID; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN P; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DUODENUM; DUODENUM BIOPSY; ENTERITIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SYSTEMIC DISEASE;

ADOLESCENT; CHILD; CROHN DISEASE; CYTOCHROME P-450 CYP3A; DUODENUM; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATION; MALE; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33747439382     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/00054725-200608000-00011     Document Type: Article

References (28)

1. Shanahan F. Crohn's disease. Lancet. 2002;359:62-69.
2. Head K, Jurenka J. Inflammatory bowel disease. II. Crohn's disease: pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2004;9:360-401.
3. Fernandez C, Buyse M, German-Fattel M, et al. Influence of the proinflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharmaceut Sci. 2004;7:359-371.
4. De Jong DJ, van der Logt EMJ, van Schaik A, et al. Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase. Gut. 2003;52:547-551.
5. Pelkonen O, Boobis AR, Gundert-Remy U. In Vitro Prediction of Gastrointestinal Absorption and Bioavailability. Paper presented at the COST B15 Meeting, Berlin, Germany, May 5-6, 2000.
6. Wacher VJ, Silverman JA, Zhang YC, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998;87:1322-1330.
7. Koch I, Weil R, Wolbold R, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Disp. 2002;30:1108-1114.
8. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today. 2001;6:835-839.
9. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit. 2000;22:137-140.
10. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev. 2001;50(Suppl 1):S3-S11.
11. Pascussi J-M, Gerbal-Chaloin S, Pichard-Garcia L, et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun. 2000;274:707-713.
12. Kalitsky-Szirtes J, Shayeganpour A, Broks DR, et al. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos. 2004;32:20-27.
13. Belliard AM, Tardivel S, Farinotti R, et al. Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells. J Pharm Pharmacol. 2002;54:1103-1109.
14. Bertilsson PM, Olsson P, Magnusson KE. Cytokines influence mRNA expression of Cytochrome P450 3A and MDR1 in intestinal cells. J Pharm Sci. 2001;90:638-646.
15. Schurmann G, Betzler M, Post S, et al. Soluble interleukine-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes in serum concentrations. Digestion. 1992;51:51-59.
16. Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn's disease. Gut. 2005;54:488-495.
17. Shimamoto Y, Kitamura H, Hoshi H, et al. Differential alterations in levels of hepatic microsomal Cytochrome P450 isozymes following intracerebroventricular injection of bacterial lipopolysaccharide in rats. Arch Toxicol. 1998;72:492-498.
18. Goralski KB, Hartmann G, Piquette-Miller M, et al. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol. 2003;39:35-48.
19. Beigneux AP, Moser AH, Shigenaga JK, et al. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun. 2002;293:145-149.
20. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993;44:707-715.
21. Bonhome-Faivre L, Castagne V, Urien S, et al. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice. Drug Metab Dispos. 2004;32:168-171.
22. Belliard AM, Lacour B, Farinotti R, et al. Effect of tumor necrosis factor-α and interferon-γ on intestinal P-glycoprotein expression, activity and localization in Caco-2 cells. J Pharm Sci. 2004;93:1524-1536.
23. Silva MA, Menezes J, Wizman S, et al. Cytokine tissue levels as markers of disease activity in pediatric Crohn disease. Pediatr Res. 2003;54:456-461.
24. Saclarides TJ, Jakate SM, Coon JS, et al. Variable expression of P-glycoprotein in normal, inflamed and dysplastic areas in ulcerative colitis. Dis Colon Rectum. 1992;35:747-752.
25. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127:26-40.
26. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
27. Paulussen A, Lavrijsen K, Bohets H. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics. 2000;10:415-424.
28. Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos. 2005;33:1603-1607.